FAQs
-
What is the AR-V7 Nucleus Detect® test?
-
Who is eligible?
-
Am I eligible if I have already had treatment with enzalutamide or abiraterone acetate?
-
What causes resistance to enzalutamide or abiraterone acetate?
-
What kind of treatment will I get if I am resistant to enzalutamide or abiraterone acetate?
-
How long will it take to get the results of the AR-V7 Nucleus Detect test?
-
Is the AR-V7 Nucleus Detect test covered by insurance?
Learn how the AR-V7 Nucleus Detect test puts AR-targeted therapy to the test
Learn about the AR-V7 Nucleus Detect testing process
See FAQs about the AR-V7 Nucleus Detect test
98%
AR-V7 Nucleus Detect test patients have $0 financial responsibility†
This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Your cost-sharing amounts, including deductibles and copays, will vary by plan and coverage type. Only your insurer can confirm if and how the AR-V7 Nucleus Detect test will be covered.
99%
of AR-V7 Nucleus Detect test patients have a financial responsibility of <$100†
This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Patients with high-deductible plans may receive a bill for most or all the cost of the Oncotype DX AR-V7 Nucleus Detect test if they have not satisfied their deductible.
Learn about costs, coverage, and how Exact Sciences can help
*Testing performed at Epic Sciences, Inc., 9381 Judicial Drive, Suite 200, San Diego, CA 92121.
†The numbers cited are based on historical patient billing data from 1/02/2021 to 12/31/2021. Rates of coverage vary by state and region. Exceptions for coverage may apply. Exact Sciences strongly encourages patients to contact their insurer with questions about AR-V7 Nucleus Detect test coverage.